All Videos

Eichenfield discusses high skin clearance and safety in teens with psoriasis, per new ICONIC-LEAD phase 3 data.

Raj Chovatiya, MD, PhD, MSCI, reviews the benefits of Revolutionizing Atopic Dermatitis as a disease-specific conference.

Panelists discuss how poorly managed generalized pustular psoriasis (GPP) flares can lead to recurrent hospitalizations and significant morbidity, while reviewing Effisayil 2 trial results that demonstrated the effectiveness of maintenance therapy in preventing flares and sustaining long-term disease control through targeted inhibition of the IL-36 pathway.

Panelists discuss how a generalized pustular psoriasis (GPP) emergency case highlights the rapid onset, systemic complications, and treatment challenges of this condition, while reviewing Effisayil 1 trial results that demonstrated spesolimab’s efficacy in quickly resolving pustulation through IL-36 pathway inhibition, representing a significant advancement in targeted therapy for acute flares.

Untreated or undertreated AD can lead to poor sleep, infections, and stunted development.

Panelists discuss how long-term data confirm the sustained efficacy and safety of IL-17 inhibitors in psoriasis. Secukinumab (Bissonnette, 2018; Langley, 2022) and ixekizumab (Blauvelt, 2021) show durable PASI responses over 5 years. Brodalumab’s 5-year pharmacovigilance (Lebwohl, 2024) and 120-week data (Puig, 2020) support its long-term use. Bimekizumab’s 4-year data (Blauvelt, 2024; Gordon, 2024) demonstrate continued efficacy, with 5-year results anticipated at AAD 2025.

Panelists discuss how to identify suitable patients for JAK inhibitor therapy by evaluating disease severity, medical history, risk factors, and individual treatment goals while considering contraindications and safety considerations.

Jennifer Soung, MD, discusses how convenience and ease of use influence treatment adherence and how a new topical JAK inhibitor could enhance real-world outcomes by simplifying application and improving patient compliance.

Jennifer Soung, MD, discusses how ruxolitinib cream, if approved for use in ages 2–11, could become a valuable addition to the treatment landscape for pediatric atopic dermatitis by offering a non-steroidal option for managing inflammation and symptoms.

Jennifer Soung, MD, discusses how having more nonsteroidal options for long-term atopic dermatitis management is crucial, especially for younger children, to minimize potential side effects and support safer, sustained treatment.

Jennifer Soung, MD, discusses how the biggest frustrations parents express about current treatment options for their children with AD, including limited effectiveness, side effects, and the lack of long-term solutions.

Panelists discuss how individual patient characteristics, including comorbidities, treatment history, and personal preferences, guide therapeutic decision-making for a 38-year-old woman with severe atopic dermatitis.

Panelists discuss how when prescribing an IL-17 inhibitor, key safety considerations include infection risk (particularly tuberculosis and fungal infections), inflammatory bowel disease exacerbation, allergic reactions, neutropenia, immunogenicity, vaccination timing, pregnancy/breastfeeding status, malignancy history, and monitoring requirements for adverse events.

Jennifer Soung, MD, discusses how pediatric atopic dermatitis (AD) burdens entire families through sleep disruption and emotional toll. Parents seek effective nonsteroidal options beyond current treatments. Convenient topical Janus kinase (JAK) inhibitors could improve adherence and outcomes.

An expert discusses whether the 31-gene expression profile (GEP) risk classification would change treatment guidelines and how the patient’s GEP risk level would influence the approach to surveillance and follow-up.

For Rosacea Awareness Month, Zoe Diana Draelos, MD, spoke to Dermatology Times about skinbetter’s Mystro Active Balance Serum and its NRS Seal of Acceptance.

Raj Chovatiya, MD, PhD, MSCI, discusses his approach to diagnosing and treating chronic hand eczema.

Treatment decisions are increasingly guided by patient values, preferences, and quality-of-life considerations.

Panelists discuss how prior and current treatments for patients with generalized pustular psoriasis (GPP) have evolved from traditional systemic therapies with significant limitations to newer targeted biologics and small molecules that specifically address the underlying IL-36 pathway dysregulation, offering improved efficacy and safety profiles for this rare but severe condition.

Panelists discuss how recognizing the flares and triggers of generalized pustular psoriasis requires vigilant monitoring for warning signs such as fever, malaise, and spreading erythema, while understanding that common precipitating factors include medication withdrawals, infections, pregnancy, and certain drugs that can rapidly transform stable disease into acute, potentially life-threatening episodes requiring immediate intervention.

Current JAK inhibitors are approved only for those 12 and older, leaving younger patients without access.

Allergan’s latest initiative hopes to empower both patients and clinicians while advancing industry standards, according to Sherket Peterson, PhD.

Sherket Peterson, PhD, spoke to Dermatology Times about Allergan’s recent research and plan to launch a universal skin quality index.

Panelists discuss how IL-17 inhibitors are generally well-tolerated, but common adverse effects include infections, particularly candidiasis, and potential increased suicidal ideation risk. Patients should be informed of candidiasis risk, especially with bimekizumab (Gordon, 2022), and monitored for mood changes, as IL-17s and IL-23s may impact mental health (Blauvelt, 2023). Open discussions help assess risks while ensuring treatment benefits.

Panelists discuss how IL-17 inhibitors are considered for plaque psoriasis based on disease severity, comorbidities, and patient preference. Selection factors include efficacy, safety, access, and cost. Clinical trial data guide choices, but real-world factors impact use. Dosing varies: secukinumab (300 mg weekly for 5 weeks, then monthly), ixekizumab (160 mg at week 0, then 80 mg biweekly for 12 weeks, then monthly), brodalumab (210 mg weekly for 3 weeks, then biweekly), and bimekizumab (320 mg every 4 weeks for 16 weeks, then every 8 weeks). Dosing and device options influence prescribing decisions.

An expert discusses when gene expression profile (GEP) testing is recommended for melanoma and squamous cell carcinoma (SCC) patients, including cases where it may not be necessary, and provides final thoughts on the utility of GEP testing in risk stratification and making treatment decisions.

An expert discusses their impressions of the case, classifying the patient’s risk based on the clinical presentation of the lesion, and outlines treatment recommendations without knowing the 40-gene expression profile (GEP) information, including whether adjuvant therapy (ART) would be recommended. The expert also shares how to discuss 40-GEP testing with patients and reassure them that accurate risk levels are crucial for receiving optimal treatment.

Panelists discuss how to optimize treatment outcomes by managing the transition from biologics to JAK inhibitors and considering dose adjustment strategies when patients show inadequate response to initial therapy.

Aaron Farberg, MD, discuss how to educate parents about the potential adverse effects of a new therapy while also reassuring them about its overall safety profile by providing clear, evidence-based information and emphasizing the rigorous testing and monitoring processes.

Aaron Farberg, MD, discuss how appropriate monitoring, including regular assessments of growth, potential side effects, and laboratory tests to evaluate liver function and hematologic parameters, would be necessary when prescribing a topical JAK inhibitor to a younger child (age 2-11 years).